

Special Issue

Nanomedicine & Immunotherapy: The Grail for Cancer Treatment?

Message from the Guest Editors

Cancer continues to represent a significant socio-economic and health problem worldwide. Despite the advances in diagnosis and treatment, most patients do not respond to or become resistant to conventional treatments or relapse. The advent of immunotherapy has encouraged patient-targeted treatment. However, some gaps in knowledge remain, namely cancer immune editing/exhaustion issues and adverse immunotoxicity events. Therefore, combining conventional therapies with nanomedicine has gained ground in the scientific community. Nanomedicine explores the potential of applying nanotechnology to medicine via triggering the release of cargos, such as imaging and therapeutic agents, for cancer-patient-personalized diagnosis, treatment, and monitoring. Consequently, merging immunotherapy and nanomedicine may constitute a direction for improving cancer diagnosis and treatment, focusing on cancer cells and the surrounding tumor microenvironment. Hence, cordially invite researchers to submit original research or review manuscripts that present up-to-date data on immunotherapy and nanomedicine applications for cancer prevention and management.

Guest Editors

Dr. Cátia Domingues

Dr. Ana Figueiras

Dr. Ivana Jarak

Deadline for manuscript submissions

closed (30 September 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/153012

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).